Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Long Term Evaluation of Sarilumab in Rheumatoid Arthritis Patients (SARIL-RA-EXTEND)

ClinicalTrials.gov ID: NCT01146652

Public ClinicalTrials.gov record NCT01146652. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 1, 2026, 10:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multi-center, Uncontrolled Extension Study Evaluating Efficacy and Safety of SAR153191 in Patients With Active Rheumatoid Arthritis (RA)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Main Study: Primary Objective: Assess the long term safety of sarilumab in participants with rheumatoid arthritis (RA). Secondary Objective: Assess the long term efficacy of sarilumab in participants with RA. Sub-Study: This phase 3, open label sub-study was aimed to assess the usability of PFS-S when used by participants with moderate or severe RA, or their professional or non-professional healthcare providers in an unsupervised real-world situation. To mimic the real-world practice, the sub-study was incorporated into the LTS11210 study without additional visits compared to the scheduled visits in the main study. The duration of this sub-study was 12 weeks.

Study identification

NCT ID
NCT01146652
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Sanofi
Industry
Enrollment
2,023 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 20, 2010
Primary completion
Dec 30, 2020
Completion
Dec 30, 2020
Last update posted
Mar 27, 2022

2010 – 2020

United States locations

U.S. sites
75
U.S. states
27
U.S. cities
69
Facility City State ZIP Site status
Investigational Site Number 840070 Anniston Alabama 36207
Investigational Site Number 840138 Birmingham Alabama 35205
Investigational Site Number 840152 Huntsville Alabama 35801
Investigational Site Number 840072 Gilbert Arizona 85234
Investigational Site Number 840141 Glendale Arizona 85304
Investigational Site Number 840134 Fullerton California 92835
Investigational Site Number 840008 La Jolla California 92093
Investigational Site Number 840135 San Diego California 92120
Investigational Site Number 840021 Santa Maria California 94354
Investigational Site Number 840100 Stanford California 94305
Investigational Site Number 840049 Upland California 91786
Investigational Site Number 840151 Colorado Springs Colorado 80903
Investigational Site Number 840130 Lewes Delaware 19958
Investigational Site Number 840153 Aventura Florida 33180
Investigational Site Number 840050 Clearwater Florida 35765
Investigational Site Number 840033 Fort Lauderdale Florida 33309
Investigational Site Number 840041 Gainesville Florida 32608
Investigational Site Number 840067 Jupiter Florida 33458
Investigational Site Number 840048 Miami Florida 33155
Investigational Site Number 840024 Naples Florida 34102
Investigational Site Number 840006 Orlando Florida 32806
Investigational Site Number 840128 Ormond Beach Florida 32174
Investigational Site Number 840063 Palm Harbor Florida 34684
Investigational Site Number 840155 Palm Harbor Florida 34684
Investigational Site Number 840060 Sarasota Florida 34239
Investigational Site Number 840140 Tampa Florida 33614
Investigational Site Number 840126 Vero Beach Florida 32960
Investigational Site Number 840003 Atlanta Georgia 30322
Investigational Site Number 840028 Decatur Georgia 30033
Investigational Site Number 840027 Marietta Georgia 30060
Investigational Site Number 840018 Idaho Falls Idaho 83404
Investigational Site Number 840046 Chicago Illinois 60612
Investigational Site Number 840052 Kansas City Kansas 66160-7321
Investigational Site Number 840230 Elizabethtown Kentucky 42701
Investigational Site Number 840015 Lexington Kentucky 40504
Investigational Site Number 840120 Baton Rouge Louisiana 70809
Investigational Site Number 840109 Lake Charles Louisiana 70601
Investigational Site Number 840055 Frederick Maryland 21702
Investigational Site Number 840013 Wheaton Maryland 20902
Investigational Site Number 840154 Boston Massachusetts 02115
Investigational Site Number 840150 Lansing Michigan 48910
Investigational Site Number 840137 Saint Clair Shores Michigan 48081
Investigational Site Number 840112 Lincoln Nebraska 68516
Investigational Site Number 840026 Freehold New Jersey 07728
Investigational Site Number 840115 Lake Success New York 11042
Investigational Site Number 840056 New York New York 10003
Investigational Site Number 840043 New York New York 11201
Investigational Site Number 840106 Orchard Park New York 14127
Investigational Site Number 840118 Smithtown New York 11787
Investigational Site Number 840116 Wilmington North Carolina 28401
Investigational Site Number 840233 Minot North Dakota 58701
Investigational Site Number 840002 Oklahoma City Oklahoma 73103
Investigational Site Number 840127 Oklahoma City Oklahoma 73103
Investigational Site Number 840011 Tulsa Oklahoma 74104
Investigational Site Number 840065 Tulsa Oklahoma 74135
Investigational Site Number 840010 Bethlehem Pennsylvania 18015
Investigational Site Number 840009 Duncansville Pennsylvania 16635
Investigational Site Number 840062 Reading Pennsylvania 19611
Investigational Site Number 840058 Columbia South Carolina 29204
Investigational Site Number 840016 North Charleston South Carolina 29406
Investigational Site Number 840025 Jackson Tennessee 38305
Investigational Site Number 840059 Memphis Tennessee 38119
Investigational Site Number 840032 Amarillo Texas 79124
Investigational Site Number 840038 Austin Texas 78705
Investigational Site Number 840001 Dallas Texas 75231
Investigational Site Number 840022 Dallas Texas 75235
Investigational Site Number 840012 Dallas Texas 75390
Investigational Site Number 840129 Houston Texas 77074
Investigational Site Number 840069 Lubbock Texas 79424
Investigational Site Number 840074 Mesquite Texas 75150
Investigational Site Number 840020 Nassau Bay Texas 77058
Investigational Site Number 840103 San Antonio Texas 78217
Investigational Site Number 840036 Spokane Washington 99204
Investigational Site Number 840061 Tacoma Washington 98405
Investigational Site Number 840124 Clarksburg West Virginia 26301

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 260 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01146652, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 27, 2022 · Synced Sep 1, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01146652 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →